Monthly
US$200
Billed every month
Timolol Maleate Eye Drops(马来酸噻吗洛尔滴眼液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders0View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers33View records ↓
API companies with A status7View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 33 distinct approval numbers and 25 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东众生药业股份有限公司 | 国药准字H20178006 | 5ml:25mg(以噻吗洛尔计) | Category A (甲) | XS01EDS008G010010100371 | NHSA |
| 天津市中央药业有限公司 | 国药准字H12020054 | 5ml:12.5mg | Category A (甲) | XS01EDS008G010010100928 | NHSA |
| 亚邦医药股份有限公司 | 国药准字H32020377 | 5ml:12.5mg | Category A (甲) | XS01EDS008G010010101510 | NHSA |
| 江苏云阳集团药业有限公司 | 国药准字H32020313 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010101519 | NHSA |
| 江苏颐海药业有限责任公司 | 国药准字H32020535 | 5ml:12.5mg | Category A (甲) | XS01EDS008G010010101730 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20053459 | 0.4ml:1mg | Category A (甲) | XS01EDS008G010010101791 | NHSA |
| 湖北潜江制药股份有限公司 | 国药准字H20065130 | 5ml:12.5mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010101840 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20045947 | 5ml:12.5mg | Category A (甲) | XS01EDS008G010010101967 | NHSA |
| 武汉五景药业有限公司 | 国药准字H42021078 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010101978 | NHSA |
| 成都恒瑞制药有限公司 | 国药准字H20063099 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010102031 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20243071 | 0.5%(5ml:25mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010010102733 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254418 | 0.25%(0.3ml:0.75mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010010102763 | NHSA |
| 津药永光(河北)制药有限公司 | 国药准字H20063920 | 5ml:25mg | Category A (甲) | XS01EDS008G010010102817 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H20093786 | 0.25%(5ml:12.5mg,按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010103139 | NHSA |
| 长春长庆药业集团有限公司 | 国药准字H22020431 | 5ml:25mg | Category A (甲) | XS01EDS008G010010103299 | NHSA |
| 山东博士伦福瑞达制药有限公司 | 国药准字H20023109 | 5ml:25mg;8ml:40mg;10ml:50mg | Category A (甲) | XS01EDS008G010010104072 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010104127 | NHSA |
| 安徽省双科药业有限公司 | 国药准字H20045418 | 5ml:25mg | Category A (甲) | XS01EDS008G010010104335 | NHSA |
| 合肥立方制药股份有限公司 | 国药准字H20253876 | 0.5%(5ml:25mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010010104394 | NHSA |
| 合肥利民制药有限公司 | 国药准字H34022763 | 5ml:25mg | Category A (甲) | XS01EDS008G010010104423 | NHSA |
| 宁夏康亚药业股份有限公司 | 国药准字H20093905 | 0.25% | Category A (甲) | XS01EDS008G010010105911 | NHSA |
| 江苏远恒药业有限公司 | 国药准字H20249112 | 0.25%(5ml:12.5mg)(按C13H24N4O3S计) | Category A (甲) | XS01EDS008G010010106033 | NHSA |
| 广东宏盈科技有限公司 | 国药准字H20133308 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010107415 | NHSA |
| 扬州中宝药业股份有限公司 | 国药准字H20254927 | 0.5%(0.3ml:1.5mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010010181161 | NHSA |
| 天津市中央药业有限公司 | 国药准字H12020053 | 5ml:25mg | Category A (甲) | XS01EDS008G010010200928 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20053459 | 0.4ml:1mg | Category A (甲) | XS01EDS008G010010201791 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010010204127 | NHSA |
| 扬州中宝药业股份有限公司 | 国药准字H20254927 | 0.5%(0.3ml:1.5mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010010281161 | NHSA |
| 广东松下药业有限公司 | 国药准字H44024066 | 5ml:12.5mg | Category A (甲) | XS01EDS008G010020100389 | NHSA |
| 江苏颐海药业有限责任公司 | 国药准字H32020534 | 5ml:25mg | Category A (甲) | XS01EDS008G010020101730 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20045948 | 5ml:25mg | Category A (甲) | XS01EDS008G010020101967 | NHSA |
| 武汉新瑞医药科技有限公司 | 国药准字H20234367 | 0.5%(5ml:25mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010020101978 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20243072 | 0.25%(5ml:12.5mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010020102733 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254432 | 0.5%(0.3ml:1.5mg,按C₁₃H₂₄N₄O₃S计) | Category A (甲) | XS01EDS008G010020102763 | NHSA |
| 山东博士伦福瑞达制药有限公司 | 国药准字H20023109 | 5ml:25mg;8ml:40mg;10ml:50mg | Category A (甲) | XS01EDS008G010020104072 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010020104127 | NHSA |
| 江苏远恒药业有限公司 | 国药准字H20249113 | 0.5%(5ml:25mg)(按C13H24N4O3S计) | Category A (甲) | XS01EDS008G010020106033 | NHSA |
| 广东宏盈科技有限公司 | 国药准字H20133308 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010020107415 | NHSA |
| 广东松下药业有限公司 | 国药准字H44024067 | 5ml:25mg | Category A (甲) | XS01EDS008G010020200389 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010020204127 | NHSA |
| 山东博士伦福瑞达制药有限公司 | 国药准字H20023109 | 5ml:25mg;8ml:40mg;10ml:50mg | Category A (甲) | XS01EDS008G010030104072 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010030104127 | NHSA |
| 广东宏盈科技有限公司 | 国药准字H20133308 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010030107415 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H37022028 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010030204127 | NHSA |
| 广东宏盈科技有限公司 | 国药准字H20133308 | 5ml:25mg(按噻吗洛尔计) | Category A (甲) | XS01EDS008G010040107415 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 2 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 成都普什制药有限公司 | CYHS2602494 | Generic | 2026/10/12 | Not stated by source | CDE |
| 成都普什制药有限公司 | CYHS2602493 | Generic | 2026/10/12 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2601324 | Generic | 2026/06/08 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2502062 | Generic | 2025/06/11 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 成都普什制药有限公司 | CYHS2602494 | Generic | 2026/10/12 | Not stated by source | CDE |
| 成都普什制药有限公司 | CYHS2602493 | Generic | 2026/10/12 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2601324 | Generic | 2026/06/08 | Not stated by source | CDE |
API registrations
Non-component matches: 7 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 噻吗洛尔半水合物 | 汉瑞药业（荆门）有限公司 | Y20260000035 | I | Salt-normalized ingredient | 2026/01/26 | CDE |
| 马来酸噻吗洛尔 | PCAS | Y20250000663 | I | Exact ingredient | 2025/11/13 | CDE |
| 马来酸噻吗洛尔 | 浙江江北南海药业有限公司 | Y20250000067 | I | Exact ingredient | 2025/05/28 | CDE |
| 马来酸噻吗洛尔 | 天津民祥药业有限公司 | Y20230001317 | A | Exact ingredient | 2025/05/20 | CDE |
| 马来酸噻吗洛尔 | 江苏慈星药业有限公司 | Y20220001347 | A | Exact ingredient | 2024/01/17 | CDE |
| 马来酸噻吗洛尔 | 石家庄格瑞药业有限公司 | Y20220000253 | A | Exact ingredient | 2024/11/05 | CDE |
| 马来酸噻吗洛尔 | Fareva La Vallee | Y20190000119 | A | Exact ingredient | 2024/11/07 | CDE |
| 马来酸噻吗洛尔 | 天津力生制药股份有限公司 | Y20190007964 | A | Exact ingredient | 2025/06/28 | CDE |
| 马来酸噻吗洛尔 | 天津民祥生物医药股份有限公司 | Y20170002259 | A | Exact ingredient | 2024/05/01 | CDE |
| 马来酸噻吗洛尔 | Centaur Pharmaceuticals Private Limited | Y20170000577 | A | Exact ingredient | 2024/12/31 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/12Accepted
-
2026/10/12Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Timolol Maleate Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy